Reasons Behind AbbVie's Stock Decline on Friday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 01 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
Earnings Performance: AbbVie reported a third-quarter revenue of nearly $15.78 billion, a 9% year-over-year increase, driven by strong sales of blockbuster drugs like Skyrizi and Rinvoq, but the stock fell over 4% due to lower-than-expected profitability guidance.
Analyst Expectations: Despite exceeding revenue and net income estimates, AbbVie's raised adjusted net income guidance for 2025 remains below analyst expectations, leading to investor disappointment.
CEO's Statement: CEO Robert Michael highlighted the company's momentum and progress in advancing its pipeline and innovation, which are crucial for AbbVie's long-term growth.
Investment Considerations: The Motley Fool's Stock Advisor did not include AbbVie in its current list of top stocks to buy, suggesting investors consider other options for potentially higher returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 227.010
Low
223.00
Averages
252.00
High
289.00
Current: 227.010
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
- Clinical Trial Success: UCB's Bimzelx achieved the primary endpoint ACR50 in the BE BOLD trial for psoriatic arthritis, demonstrating over 50% improvement and indicating its superiority over AbbVie's Skyrizi, which could significantly enhance UCB's competitive position in the biopharmaceutical market.
- Patient Recruitment: The trial enrolled over 500 adults with active psoriatic arthritis, ensuring the reliability and broad applicability of the data, thereby strengthening Bimzelx's market recognition as an effective treatment option.
- Good Safety Profile: UCB reported that Bimzelx has a well-tolerated safety profile with no new safety signals, providing strong support for its market promotion and patient acceptance, which may drive future sales growth.
- Broad Market Prospects: This trial marks the fourth head-to-head study showing Bimzelx's superiority in psoriatic disease and the first in PsA, indicating UCB's ongoing innovation capabilities and market potential in this therapeutic area.
See More
Investment Opportunities Amid Market Volatility
- AbbVie's Defensive Nature: AbbVie boasts a vast portfolio of medicines, and despite economic downturns, the demand for therapies addressing chronic autoimmune diseases and cancer remains strong, ensuring stable revenue and earnings, thus providing investors with a sense of security during market declines.
- AbbVie's Dividend King Status: As a Dividend King with 50 consecutive years of dividend increases, AbbVie demonstrates its ability to maintain dividend payments even in tough economic times, helping investors smooth out losses and enhancing its appeal amid market volatility.
- Microsoft's Stable Revenue: Although Microsoft operates in a cyclical industry, its office software products are integral to daily life for individuals and businesses, allowing it to maintain a steady revenue stream even during economic recessions, showcasing the resilience of its business model.
- Growth Potential in Cloud and AI: Microsoft's leadership in cloud computing and artificial intelligence provides strong growth prospects, and while it may face challenges during economic slowdowns, investors can still expect superior returns in the long run, making it an attractive investment opportunity.
See More
Dublin Data Center First to Use Independent Microgrid in Europe
- Microgrid Innovation: The Dublin facility, a collaboration between AVK and Pure Data Centre Group, establishes Europe's first independent microgrid data center with an estimated total investment of €1 billion, aimed at addressing power connection delays and promoting sustainable development in data centers.
- Rising Energy Demand: The European Commission estimates that by 2040, at least €1.2 trillion will be needed to meet growing energy demands, with data centers consuming 22% of Ireland's power in 2024, highlighting their pressure on the national grid.
- Policy Changes Impact: The Irish government has eased the moratorium on new data center applications, mandating that new facilities provide dispatchable power or energy storage capacity, which promotes the adoption of microgrids and reflects a reassessment of the AI industry's potential.
- Market Growth Potential: The global microgrid market is projected to reach $29 billion by 2025, with Europe's market expected to grow nearly 10% annually, providing new investment opportunities for companies like AVK and driving technological advancements in the data center sector.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
SPYM ETF 52-Week Price Analysis
- Price Range Analysis: SPYM ETF's 52-week low is $56.6699 and high is $82.1079, with the latest trade at $78.12, indicating significant price fluctuations over the past year that can help investors assess market performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper technical insights, aiding in more informed investment decisions, although the specific 200-day moving average value is not mentioned in the article.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, providing high liquidity in the market.
- Monitoring Inflows and Outflows: Weekly monitoring of changes in ETF units focuses on notable inflows (new units created) or outflows (old units destroyed), with these dynamics potentially impacting not only the ETF itself but also the individual stocks held within it.
See More
AbbVie Shares Dip Following Phase 1 Study Results of ABBV-295
- Obesity Drug Progress: AbbVie reported in its Phase 1 study that ABBV-295 demonstrated clinically meaningful, dose-dependent weight reductions, with mean percentage changes ranging from -7.75% to -9.79% at week 12, highlighting the drug's potential despite overall market pressures.
- Market Performance Pressure: AbbVie shares fell 0.25% to $229.52 amid a broader market decline, although the stock has increased by 6.06% over the past 12 months, indicating a strong long-term trend.
- Technical Analysis Signals: The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, suggesting some short-term strength, but with an RSI of 53.14 indicating neutral territory, caution is advised for investors.
- Analyst Ratings Optimistic: Despite stock fluctuations, AbbVie holds a “Buy” rating with an average price target of $241.24, with recent positive targets set by RBC Capital and Barclays, reflecting market confidence in its future performance.
See More
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
- Clinical Trial Success: UCB's Bimzelx achieved the primary endpoint ACR50 in the BE BOLD trial for psoriatic arthritis, demonstrating over 50% improvement and indicating its superiority over AbbVie's Skyrizi, which could significantly enhance UCB's competitive position in the biopharmaceutical market.
- Patient Recruitment: The trial enrolled over 500 adults with active psoriatic arthritis, ensuring the reliability and broad applicability of the data, thereby strengthening Bimzelx's market recognition as an effective treatment option.
- Good Safety Profile: UCB reported that Bimzelx has a well-tolerated safety profile with no new safety signals, providing strong support for its market promotion and patient acceptance, which may drive future sales growth.
- Broad Market Prospects: This trial marks the fourth head-to-head study showing Bimzelx's superiority in psoriatic disease and the first in PsA, indicating UCB's ongoing innovation capabilities and market potential in this therapeutic area.
See More
Investment Opportunities Amid Market Volatility
- AbbVie's Defensive Nature: AbbVie boasts a vast portfolio of medicines, and despite economic downturns, the demand for therapies addressing chronic autoimmune diseases and cancer remains strong, ensuring stable revenue and earnings, thus providing investors with a sense of security during market declines.
- AbbVie's Dividend King Status: As a Dividend King with 50 consecutive years of dividend increases, AbbVie demonstrates its ability to maintain dividend payments even in tough economic times, helping investors smooth out losses and enhancing its appeal amid market volatility.
- Microsoft's Stable Revenue: Although Microsoft operates in a cyclical industry, its office software products are integral to daily life for individuals and businesses, allowing it to maintain a steady revenue stream even during economic recessions, showcasing the resilience of its business model.
- Growth Potential in Cloud and AI: Microsoft's leadership in cloud computing and artificial intelligence provides strong growth prospects, and while it may face challenges during economic slowdowns, investors can still expect superior returns in the long run, making it an attractive investment opportunity.
See More
Dublin Data Center First to Use Independent Microgrid in Europe
- Microgrid Innovation: The Dublin facility, a collaboration between AVK and Pure Data Centre Group, establishes Europe's first independent microgrid data center with an estimated total investment of €1 billion, aimed at addressing power connection delays and promoting sustainable development in data centers.
- Rising Energy Demand: The European Commission estimates that by 2040, at least €1.2 trillion will be needed to meet growing energy demands, with data centers consuming 22% of Ireland's power in 2024, highlighting their pressure on the national grid.
- Policy Changes Impact: The Irish government has eased the moratorium on new data center applications, mandating that new facilities provide dispatchable power or energy storage capacity, which promotes the adoption of microgrids and reflects a reassessment of the AI industry's potential.
- Market Growth Potential: The global microgrid market is projected to reach $29 billion by 2025, with Europe's market expected to grow nearly 10% annually, providing new investment opportunities for companies like AVK and driving technological advancements in the data center sector.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
SPYM ETF 52-Week Price Analysis
- Price Range Analysis: SPYM ETF's 52-week low is $56.6699 and high is $82.1079, with the latest trade at $78.12, indicating significant price fluctuations over the past year that can help investors assess market performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper technical insights, aiding in more informed investment decisions, although the specific 200-day moving average value is not mentioned in the article.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, providing high liquidity in the market.
- Monitoring Inflows and Outflows: Weekly monitoring of changes in ETF units focuses on notable inflows (new units created) or outflows (old units destroyed), with these dynamics potentially impacting not only the ETF itself but also the individual stocks held within it.
See More
AbbVie Shares Dip Following Phase 1 Study Results of ABBV-295
- Obesity Drug Progress: AbbVie reported in its Phase 1 study that ABBV-295 demonstrated clinically meaningful, dose-dependent weight reductions, with mean percentage changes ranging from -7.75% to -9.79% at week 12, highlighting the drug's potential despite overall market pressures.
- Market Performance Pressure: AbbVie shares fell 0.25% to $229.52 amid a broader market decline, although the stock has increased by 6.06% over the past 12 months, indicating a strong long-term trend.
- Technical Analysis Signals: The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, suggesting some short-term strength, but with an RSI of 53.14 indicating neutral territory, caution is advised for investors.
- Analyst Ratings Optimistic: Despite stock fluctuations, AbbVie holds a “Buy” rating with an average price target of $241.24, with recent positive targets set by RBC Capital and Barclays, reflecting market confidence in its future performance.
See More
